

Xingmin Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6654700/publications.pdf>

Version: 2024-02-01

31
papers

952
citations

623734

14
h-index

477307

29
g-index

32
all docs

32
docs citations

32
times ranked

1123
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulatory transcription factors of <i>Clostridioides difficile</i> pathogenesis with a focus on toxin regulation. <i>Critical Reviews in Microbiology</i> , 2023, 49, 334-349.	6.1	4
2	Genomic and Phenotypic Characterization of the Nontoxigenic <i>Clostridioides difficile</i> Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of <i>C. difficile</i> Infection. <i>Microbiology Spectrum</i> , 2022, 10, e0178821.	3.0	7
3	Development of an Effective Nontoxigenic <i>Clostridioides difficile</i> -Based Oral Vaccine against <i>C. difficile</i> Infection. <i>Microbiology Spectrum</i> , 2022, 10, e0026322.	3.0	8
4	On the Potential Significance of the Intrinsically Disordered Regions in the <i>Clostridioides difficile</i> Toxins A and B. <i>Current Protein and Peptide Science</i> , 2022, 23, 192-209.	1.4	2
5	<i>Clostridioides difficile</i> phage biology and application. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	8.6	43
6	Cwl0971, a novel peptidoglycan hydrolase, plays pleiotropic roles in <i>Clostridioides difficile</i> R20291. <i>Environmental Microbiology</i> , 2021, 23, 5222-5238.	3.8	10
7	Discovery of Cyclic Peptidomimetic Ligands Targeting the Extracellular Domain of EGFR. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11219-11228.	6.4	9
8	Mechanisms of antibiotic resistance of <i>Clostridioides difficile</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3077-3090.	3.0	16
9	FlhW and CsrA Govern Flagellin (FliC) Synthesis and Play Pleiotropic Roles in Virulence and Physiology of <i>Clostridioides difficile</i> R20291. <i>Frontiers in Microbiology</i> , 2021, 12, 735616.	3.5	11
10	Pathobionts: mechanisms of survival, expansion, and interaction with host with a focus on <i>Clostridioides difficile</i> . <i>Gut Microbes</i> , 2021, 13, 1979882.	9.8	26
11	Recent developments in systems biology and genetic engineering toward design of vaccines for TB. <i>Critical Reviews in Biotechnology</i> , 2021, , 1-16.	9.0	3
12	Impact of CodY protein on metabolism, sporulation and virulence in <i>Clostridioides difficile</i> ribotype 027. <i>PLoS ONE</i> , 2019, 14, e0206896.	2.5	24
13	Cwp22, a novel peptidoglycan cross-linking enzyme, plays pleiotropic roles in <i>Clostridioides difficile</i> . <i>Environmental Microbiology</i> , 2019, 21, 3076-3090.	3.8	34
14	A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of <i>Clostridioides difficile</i> Infection in Mice. <i>Frontiers in Microbiology</i> , 2019, 9, 3234.	3.5	17
15	Characterization of the virulence of a non-RT027, non-RT078 and binary toxin-positive <i>Clostridium difficile</i> strain associated with severe diarrhea. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-11.	6.5	17
16	Novel Chimeric Protein Vaccines Against <i>Clostridium difficile</i> Infection. <i>Frontiers in Immunology</i> , 2018, 9, 2440.	4.8	5
17	Oral Immunization with Nontoxigenic <i>Clostridium difficile</i> Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against <i>C. difficile</i> Infection in Both Mice and Hamsters. <i>Infection and Immunity</i> , 2018, 86, .	2.2	15
18	Bis-cyclic Guanidines as a Novel Class of Compounds Potent against <i>Clostridium difficile</i> . <i>ChemMedChem</i> , 2018, 13, 1414-1420.	3.2	11

#	ARTICLE	IF	CITATIONS
19	Facilely accessible quinoline derivatives as potent antibacterial agents. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3573-3579.	3.0	50
20	<i>Clostridioides difficile</i> Biology: Sporulation, Germination, and Corresponding Therapies for <i>C. difficile</i> Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 29.	3.9	102
21	Bioprospecting Deep-Sea Actinobacteria for Novel Anti-infective Natural Products. <i>Frontiers in Microbiology</i> , 2018, 9, 787.	3.5	28
22	TPL2 Is a Key Regulator of Intestinal Inflammation in <i>Clostridium difficile</i> Infection. <i>Infection and Immunity</i> , 2018, 86, .	2.2	10
23	Update on Antimicrobial Resistance in <i>Clostridium difficile</i> : Resistance Mechanisms and Antimicrobial Susceptibility Testing. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1998-2008.	3.9	191
24	Antibiotic Resistance and Toxin Production of <i>Clostridium difficile</i> Isolates from the Hospitalized Patients in a Large Hospital in Florida. <i>Frontiers in Microbiology</i> , 2017, 8, 2584.	3.5	34
25	A Detrimental Role of Immunosuppressive Drug, Dexamethasone, During <i>Clostridium difficile</i> Infection in Association with a Gastrointestinal Microbial Shift. <i>Journal of Microbiology and Biotechnology</i> , 2016, 26, 567-571.	2.1	11
26	Immunogenicity and protective efficacy of <i>Clostridium difficile</i> spore proteins. <i>Anaerobe</i> , 2016, 37, 85-95.	2.1	28
27	A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against <i>Clostridium difficile</i> infection in mice and hamsters. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2215-2222.	3.3	12
28	The non-toxigenic <i>Clostridium difficile</i> CD37 protects mice against infection with a BI/NAP1/027 type of <i>C. difficile</i> strain. <i>Anaerobe</i> , 2015, 36, 49-52.	2.1	15
29	A Chimeric Toxin Vaccine Protects against Primary and Recurrent <i>Clostridium difficile</i> Infection. <i>Infection and Immunity</i> , 2012, 80, 2678-2688.	2.2	81
30	Mouse Relapse Model of <i>Clostridium difficile</i> Infection. <i>Infection and Immunity</i> , 2011, 79, 2856-2864.	2.2	92
31	Antibody-Enhanced, Fc Gamma Receptor-Mediated Endocytosis of <i>Clostridium difficile</i> Toxin A. <i>Infection and Immunity</i> , 2009, 77, 2294-2303.	2.2	36